Clinical Takeaway
In this small pilot trial of 20 insomnia patients, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that cannabinoids do not straightforwardly improve sleep quantity in a clinical insomnia population. These objective EEG findings highlight an important gap between patient-reported sleep benefits and measurable sleep architecture outcomes. Clinicians should counsel patients that popular cannabinoid sleep products may not perform as expected when rigorously tested under controlled conditions.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG characterization of how a standardized THC/CBD combination acutely affects sleep architecture and cortical activity in patients with insomnia disorder, filling a critical gap between widespread clinical use and limited neurophysiological evidence. The objective quantification of sleep stage transitions and next-day alertness metrics establishes a methodological foundation for determining whether cannabinoid-based sleep interventions produce clinically meaningful improvements in sleep consolidation or carry residual cognitive impairment risks that contraindicate their use.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides valuable objective EEG data suggesting that a single dose of combined THC/CBD may influence sleep architecture in insomnia patients, though the small sample size (n=20), female predominance, and single-dose design limit generalizability and our ability to draw firm conclusions about efficacy or safety with repeated use. The ratio of THC to CBD (1:20) is notably skewed toward cannabidiol, which may not reflect typical cannabis products patients self-select, and the study does not adequately address potential next-day cognitive or psychomotor impairment, a key concern when counseling patients about safety. Importantly, we lack data on tolerance development, rebound insomnia upon discontinuation, and long-term effects on sleep quality versus acute polysomnographic changes. For clinical practice, while this research suggests cannabinoids warrant further investigation as potential adjuncts for insomnia, current evidence remains insufficient to recommend them as first-line therapy, and providers should continue emphasizing cognitive-behavioral therapy